よむ、つかう、まなぶ。
Global Health Vision of Ministry of Health, Labour and Welfare of Japan (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_42939.html |
| 出典情報 | 「厚生労働省国際保健ビジョン」の公表について（8／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
promoting stockpiling through the “Support Project for Stable Supply of
Pharmaceuticals,” which includes diversifying supply sources of APIs and securing
internal and distribution stocks. We will continue to advance these initiatives moving
forward.
③ Timeline
Regarding antimicrobial drugs, which are specified critical products, we will
consider a framework for ensuring the continuous use of domestically manufactured
APIs and strategies to secure a certain level of domestic distribution. We aim to reach
a conclusion on these matters by the end of FY2024.
(6) Appropriate contributions to international organizations and Global Health
Initiatives (GHIs)
Tuberculosis (TB), malaria, Ebola, and HIV/AIDS have a major impact on society
and the economy worldwide, transcending national borders. In recent years, COVID19, AMR, neglected tropical diseases (NTDs), and other issues have significantly
increased the need for the international community to cooperate and collaborate to
address these challenges.
Currently, the MHLW contributes to international organizations such as WHO, the
Joint United Nations Programme on HIV/AIDS (UNAIDS), and the International
Agency for Research on Cancer (IARC), as well as to GHIs, including the Global
Health Innovative Technology Fund (GHIT Fund), Coalition for Innovation in Fighting
Infectious Disease Epidemics (CEPI), Global Drug Facility (GDF), Gavi, the Vaccine
Alliance, Global Antimicrobial Research and Development Partnership (GARDP),
Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), and CARB-X
(the Biopharmaceutical Accelerator against Drug Resistance). The MHLW will
promote the strengthening of these partnerships while ensuring that each organization
make the most of the contributions to deliver their performance in effective and
efficient manner, performance in alignment with the MHLW’s contribution objectives.
(7) Promotion of international policy dialogue
To date, Japan has been actively engaged in the G7 Health Ministers’ Meeting
and the G20 Health Ministers’ Meeting to address various global health challenges.
Recently, we have discussed building and strengthening the GHAs to respond to
24
Pharmaceuticals,” which includes diversifying supply sources of APIs and securing
internal and distribution stocks. We will continue to advance these initiatives moving
forward.
③ Timeline
Regarding antimicrobial drugs, which are specified critical products, we will
consider a framework for ensuring the continuous use of domestically manufactured
APIs and strategies to secure a certain level of domestic distribution. We aim to reach
a conclusion on these matters by the end of FY2024.
(6) Appropriate contributions to international organizations and Global Health
Initiatives (GHIs)
Tuberculosis (TB), malaria, Ebola, and HIV/AIDS have a major impact on society
and the economy worldwide, transcending national borders. In recent years, COVID19, AMR, neglected tropical diseases (NTDs), and other issues have significantly
increased the need for the international community to cooperate and collaborate to
address these challenges.
Currently, the MHLW contributes to international organizations such as WHO, the
Joint United Nations Programme on HIV/AIDS (UNAIDS), and the International
Agency for Research on Cancer (IARC), as well as to GHIs, including the Global
Health Innovative Technology Fund (GHIT Fund), Coalition for Innovation in Fighting
Infectious Disease Epidemics (CEPI), Global Drug Facility (GDF), Gavi, the Vaccine
Alliance, Global Antimicrobial Research and Development Partnership (GARDP),
Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), and CARB-X
(the Biopharmaceutical Accelerator against Drug Resistance). The MHLW will
promote the strengthening of these partnerships while ensuring that each organization
make the most of the contributions to deliver their performance in effective and
efficient manner, performance in alignment with the MHLW’s contribution objectives.
(7) Promotion of international policy dialogue
To date, Japan has been actively engaged in the G7 Health Ministers’ Meeting
and the G20 Health Ministers’ Meeting to address various global health challenges.
Recently, we have discussed building and strengthening the GHAs to respond to
24